Featured Science and Communiqués
DENVER – During November’s Lung Cancer Awareness Month, the International Association for the Study of Lung Cancer (IASLC) wants to highlight the importance of immunotherapy, a form of personalized medicine and a groundbreaking tool in the fight against lung cancer.
Sorafenib Modestly Increases Progression-Free Survival But Not Overall Survival in NSCLC Patients Who Failed Previous Therapies
DENVER – Sorafenib, a tyrosine kinase inhibitor (TKI) targeting the receptors for vascular endothelial growth factor, platelet derived growth factor, and mast/stem cell growth factor, modestly increases progression-free survival (PFS), time to progression, and disease control rate in non-small cell lung cancer (NSCLC) patients who have relapsed or failed two or three previous treatment regimens.
DENVER, Colo. – The International Association for the Study of Lung Cancer (IASLC) featured several scientific abstracts during the 16th World Conference on Lung Cancer (WCLC) press program. Below are links to the releases for each individual abstract.
DENVER, Colo. — The International Association for the Study of Lung Cancer (IASLC) today issued a new statement on Tobacco Control and Smoking Cessation at the 16th World Conference on Lung Cancer (WCLC) in Denver. The statement calls for higher taxes on tobacco products, comprehensive advertising and promotion bans of all tobacco products and product regulation including pack warnings.